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Brucella abortus vaccines play a central role in bovine brucellosis control/eradication programs and have been
successfully used worldwide for decades. Strain 19 and RB51 are the approved B. abortus vaccines strains most
commonly used to protect cattle against infection and abortion. However, due to some drawbacks shown by
these vaccines much effort has been undertaken for the development of new vaccines, safer and more effective,
that could also be used in other susceptible species of animals. In this paper, we present a review of the main
aspects of the vaccines that have been used in the brucellosis control over the years and the current research
advances in the development of new B. abortus vaccines.Table of contents
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B. abortus is the main causative agent of brucellosis in
cattle, causing abortion and infertility in adult animals
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creativecommons.org/publicdomain/zero/1.0/endemic in some regions of the world such as Latin
America, Middle East, Africa and Asia [1] and respon-
sible for large economic losses due to animal and human
health problems.
Due to public health importance of brucellosis and the
damage that it causes to the livestock industry, much ef-
fort has been expended to control and eradicate the dis-
ease in cattle. The development of an efficacious vaccine
for brucellosis control/eradication has been a challenge
for scientists for many years. Despite enormous advances
and the development of B. abortus S19 and RB51 vaccines,
the search for improved vaccines has never ends. Al-
though the available vaccines are effective in controlling
brucellosis, they have numerous drawbacks, such as inter-
ference with diagnostic tests, pathogenicity for humans,
potential to cause abortion in pregnant animals, among
others. In this paper, we present a review of the main as-
pects of the vaccines that have been used in the bovine
brucellosis control and eradication over the years and
some of the current advances in the research for a new
B. abortus vaccine.
2. Vaccines, vaccination and their use in
brucellosis control and eradication programs
According to Schurig et al. [2] and Ko and Splitter [3],
an ideal vaccine against brucellosis should possess the
following characteristics: (i) be live and able to provide a
strong type 1 T helper immune response (Th1); (ii) do
not induce antibodies that interfere with the serological
tests employed in the diagnosis of infected cattle, regard-
less of route, dose of administration, age or sex of the
animals; (iii) be attenuated and do not cause disease orarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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genic for humans; (iv) be able to induce a strong and
long-lasting protection against systemic and uterine in-
fection, besides preventing abortion, even in pregnant
animals inoculated with a single dose; (v) do not lead to
seroconversion on revaccination; (vi) be stable and do not
revert virulence in vivo nor in vitro; and (vii) be inexpen-
sive, easy to produce and to administer.
Even though we still do not have an ideal vaccine, vac-
cination with available vaccine strains remains the most
successful method for the prevention and control of bru-
cellosis in cattle, being a critical component of most bru-
cellosis control and eradication programs throughout
the world [4]. Numerous countries have adopted control
measures against bovine brucellosis in order to reduce
the prevalence or eradicate the disease from domestic
livestock, in an effort to prevent transmission to humans
and mitigate economic losses. Vaccination of female calves
is the central point of any brucellosis control program,
since it has performed well in the reduction of disease
prevalence, therefore useful at the disease control stage.
Considering that vaccination alone is not enough to
control and eradicate the disease, it should be associated
with continuous elimination of infected animals, as they
are the source of new infections. Thus, besides vaccin-
ation, most bovine brucellosis eradicate programs also
include test–and–slaughter policies, surveillance and
hygiene measures [4].
The aim of vaccination is the reduction of susceptibly
individuals in the population and the success of any
vaccination program depends mainly on the effective-
ness of the vaccine used and its coverage in the target
population. Vaccines against brucellosis have been evalu-
ated with respect to their potency by three different ap-
proaches: (i) testing in laboratory animals or (ii) testing
in natural hosts experimentally challenged and (iii) test-
ing under natural conditions [5]. Of these, test in natural
hosts shows more significant response and is the only
one able to measure the efficacy of B. abortus vaccines
[6,7]. In experimental studies of vaccine efficacy, vacci-
nated and non-vaccinated controls will receive a known
infectious dose of a virulent B. abortus strain at the most
susceptible period (mid-gestation), and the protection is
measure by the ability of the vaccine in preventing abor-
tion [4]. However, it is important to emphasize that the
experimentally obtained effectiveness may differ from
field efficacy that can be influenced by other factors, such
as nutrition, environmental stress, age at vaccination,
vaccination management or immunological status [4]. Be-
sides, the above three classical methodologies, B. abortus
vaccines could also be assessed by measuring the immune
responses and determination of correlates of protection by
mathematical modeling. The identification of protection
markers can be an useful approach to screen vaccinecandidates whether validated by vaccine potency tests [8].
Since experiments involving challenge of pregnant cattle
are very expensive, time-consuming and requires large
animal biosafety level 3 facilities, the rational way for the
future of B. abortus vaccines testing and development
could be the characterization and identification of the cor-
relates of protection.
Another important aspect related to the success of
brucellosis control programs is the quality of the vaccine
used. Despite the cost of the vaccine being just one frac-
tion of the total cost of a control program, its quality will
affect directly and dramatically the outcome of the pro-
gram. Assessing the quality of live Brucella vaccines is usu-
ally based on in vitro criteria, including physico-chemical
and microbiological in vitro tests as to purity, dissociation,
and determination of pH, humidity and count of viable
bacteria [9]. Recently, genetic stability has also been pro-
posed as an additional criterion in assessing of the quality
of Brucella spp. vaccines [10–12]. Although less frequently,
immunogenicity in mouse can also be included in Brucella
vaccines tests, however not having cutoff points (protec-
tion zone) defined for RB51 vaccine [9–11] and as mouse
immune system does not accurately represent bovine im-
mune system, it is very difficult to use such data.
Attenuated B. abortus strains have demonstrated the
best results in the prevention of bovine brucellosis. B.
abortus live modified vaccines are highly effective in
decreasing transmission and production losses caused by
brucellosis, but are less effective at preventing infection
by field strains [4]. Since, abortion is the key for the brucel-
losis transmission in cattle, a vaccine that can effectively
prevent abortion is able to reduce disease transmission and
largely reduce economic losses caused by the disease.
Immunization with live modified B. abortus vaccines is
generally performed in young female calves in a single dose
by intramuscular or subcutaneous injection [5]. However,
in zones of high prevalence of brucellosis, massive vaccin-
ation, including adult cows, is performed.
It is also important to take into account that although
cattle are the main target of the vaccination against B.
abortus within bovine brucellosis control and eradication
programs, they are not the unique species infected by
this agent. Goats, feral swine, elks, bison and other
hosts can also be infected by B. abortus and some of
them are even able to sustain the disease, being consid-
ered an important source of the re-emergency of the
disease in cattle [1].
Only a few vaccines have been used massively in cattle
immunization against B. abortus, S19, RB51, 45/20 and
SR82, being S19 and RB51 the most widely used vac-
cines [4]. However, many B. abortus vaccine candidates
have been developed, including DNA, subunit, recom-
binant B. abortus and recombinant vector vaccines. All
of them are evaluated principally in mouse model [13–46],
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cines, have not been tested in cattle or were not protective
in cattle, the target species.
3. S19 vaccine
Strain 19 is a live attenuated vaccine and the first B. abor-
tus vaccine to be used extensively for bovine brucellosis
control [47]. In USA, this vaccine was used for more than
five decades from 1941 and is still being used in several
other countries [4].
Brucella abortus S19 was isolated in 1923 from milk of
a Jersey cow by Dr John Buck [48]. This virulent culture
was accidentally left out at room temperature for one
year and when tested in guinea pigs showed lower viru-
lence compared with previous tests [49]. Subsequently,
S19 showed to be highly successful in immunization of
calves [48,50]. The efficacy of B. abortus S19 was
proved by experimental tests in cattle [47,51] and under
field conditions [5,52]. Its main characteristics are stable
low pathogenicity, relatively high immunogenicity, and
moderate antigenicity [53]. Strain 19 is a smooth attenu-
ated B. abortus biovar 1 that induces antibody response
that cannot be distinguished from the antibody response
induced by infection with field strains [4,50]. The lipo-
polysaccharide (LPS) O-side chain is an immunodomi-
nant antigen to which the majority of antibodies
resulting from S19 immunization or natural infection
are directed [54]. Antibody titers resulting from vaccin-
ation may persist for a prolonged period in a small pro-
portion of vaccinated calves: approximately two animals
per 100 000 calfhood vaccinated ones [54]. Residual
antibody titers increase with the age at which the animal
was vaccinated [5], and to address this issue, vaccination
is usually performed on young female calves between
three and eight months of age [47]. However, vaccin-
ation of this age group does not appear to significantly
differ in immunity induced [47]. Restriction on age of
vaccination, due to the interference in the brucellosis
diagnosis, is the main disadvantage of vaccination with
S19. This has contributed greatly to their replacement
by RB51 vaccine strain, which does not have this
problem.
In calves, S19 vaccination can be performed with full
dose [2.5 – 12 × 1010 colony forming units (CFU)], ori-
ginal dosage used in S19 classical experiments, or with
reduced dosage (3–10 × 109 CFU) to minimize residual
antibody titers and to prevent occasional persistent vac-
cinal infection [4]. After calfhood-vaccination, S19 is usu-
ally cleared from superficial cervical lymph node within
10 to 12 weeks. Vaccination of adult cattle with S19, low
dosage (0.3-3 × 109 CFU), was also successfully employed
in infected herds [5,55,56]. S19-adult vaccination
was tested as a strategy to be used in infected herds in
order to reduce abortions and subsequently brucellosistransmission; however, it was discontinued because vac-
cination of pregnant animals can cause abortion and mainly
because of the persistence of vaccinal antibodies [56,57].
In general, after calfhood vaccination, S19 does not
persist in the reproductive tracts of mature heifers and
does not cause abortion in these animals [54]. Nonethe-
less, even with markedly infrequent occurrence, some
cattle remain chronically infected and may abort and ex-
crete the vaccine strain in the milk. Another disadvan-
tage of S19 vaccination includes the fact that in some
circumstances S19 can cause abortion in pregnant ani-
mals [57]. After vaccination of cattle with one, two or
three doses prior to breeding age, McDiarmid [51] recov-
ered S19 from 10% of milk samples and 1.5% of samples
from cases of abortion. In males, calfhood S19 vaccination
usually results in persistent antibody titers, testicular in-
fection, and hence infertility [58]. Furthermore, the vac-
cination of infected animals with S19 does not cure nor
alter the normal course of the disease [47,50].
On the other hand, duration of immunity induced by
S19 in cattle vaccinated as calves has proven to be quite
long, reaching almost the entire productive lifespan of
the animal [47,51]. The immunity in cattle vaccinated
between 6 and 8 months of age does not decrease from
the first through the fifth pregnancy [47,51]. Moreover,
revaccination experiments with S19 and killed B. abortus
vaccines demonstrated no apparent benefit in cattle-
challenge experiments compared with just S19-calfhood
immunization [47], despite McDiarmid [51] having ob-
served a small gain from S19 revaccination. Under field
conditions 82 to 95% of vaccinated cattle have been
shown to have complete protection against infection
with virulent strains [50]. However, it has also been
demonstrated that the effectiveness of the vaccine de-
creases proportionally with an increasing dose of bacter-
ial exposure [47,50].
Regarding the immune response triggered by S19
vaccination, most of our knowledge comes from mice
studies, which have been shown a strong Th1 immune
response with production of IFN-γ and high levels of
antigen-specific CD4+ and granzyme B-secreting CD8+
T-cell responses [32].
Being pathogenic to man, the utilization of S19 requires
safety training of the personal involved and the use of per-
sonal protection equipment as gloves, long sleeve coats,
protection glasses, and N95 masks.
4. RB51 vaccine strain
B. abortus strain RB51 is a rough rifampicin-resistant
strain, which exhibited a lack of expression of the LPS O-
side chains (OPS) [59]. RB51 vaccine strain was developed
in 1982 by Prof. Gerhardt Schurig’s group and is derived
from a virulent smooth B. abortus biovar 1 strain 2308
[59]. This is a natural mutant derived by a serial
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tions of rifampicin or penicillin and by selecting single
colonies with rough morphology [59]. The rough char-
acteristic is stable during in vitro and in vivo passages
and does not revert to virulent phenotype [59].
The protection against abortion and infection induced
by RB51 vaccination in cattle has been sufficiently demon-
strated under experimental conditions [6,7,60,61,64].
Also, the use of RB51 is highly effective under field condi-
tions, in herds with high and low brucellosis prevalence
[62,63].
The literature shows that calves vaccinated with RB51
at three, five and seven months of age are protected
against infection and abortion [64], as well as heifers
vaccinated at age of 10 or 24 months, after challenge
with the virulent B. abortus 2308 [6,60]. Nevertheless, it
has been suggested that under experimental circumstances
the vaccination with S19 is slightly (not significant) more
efficacious than RB51 [4,64]. After vaccination, RB51 is
usually cleared from calf superficial cervical lymph node
within 6 to 10 weeks [64]. RB51 is considered more attenu-
ated than S19, based on results of clearance and histologic
examination of infected tissues of vaccinated animals.
In general, the recommended dosage for RB51 calf-
hood vaccination is 1.0 – 3.4 × 1010 CFU [4]. Protection
against B. abortus infection is similar through the
suggested dosage, although higher antibody titers and
longer persistence of bacteria had been associated with
the full dose (3.4 × 1010 CFU) [8]. Reduced dosage
(1 × 109 CFU), generally recommended for adult animals,
also protects against infection and abortion caused by
virulent 2308 [61]. Despite RB51 having highly reduced
abortifacient characteristics [59,65], it is not completely
safe for pregnant cow, mainly when full dose is adminis-
trated [66]. However, some results indicate that non-
vaccinated cattle and cattle vaccinated with S19 as calves
can be safely vaccinated with RB51 (full dose) during the
pregnancy [6,67,68]. Furthermore, data indicates that
RB51 vaccination is a safe procedure also for males [69].
In addition, as S19 vaccine, RB51 can cause infection
in humans especially immunosuppressed individuals [70].
RB51 is resistant to rifampicin, one of the antibiotics of
choice in the treatment of human brucellosis, and failure
to be detected by routine serological tests are the two
most important points one has to be aware during diag-
nosis and treatment of humans. Therefore, the same
protective measures recommended for S19 also applies
to RB51 use.
Because of the rough phenotype, RB51 does not
induce the production of anti-OPS antibodies in immu-
nized animals, overcoming the serologic problems ob-
served after S19 vaccination [7,59,61]. Consequently,
RB51 vaccinated cattle can be easily and accurately dif-
ferentiated from naturally infected animals, allowing theeffective use of the test-and-slaughter and vaccination
policies simultaneously. Vaccination with RB51 does not
induce antibodies detectable by routine serologic brucel-
losis diagnostic tests, even after S19 calfhood vaccination
and multiple RB51 boosters or use of full dose of RB51
(3.4 × 1010 CFU) [7,61,68]. However, RB51-specific
antibodies can be detected by dot enzyme-linked im-
munosorbent assay or ELISA using killed RB51 antigens
[71,72], until approximately 12 weeks after vaccination,
with the peak occurring four weeks after vaccination
or revaccination with decreasing titers after ten weeks
[61,73]. Interestingly, S19-vaccinated cattle exhibit
higher titers against RB51 antigens in ELISA than ani-
mals vaccinated with RB51, probably due to persistence
of S19, which may result in high levels of cross-reacting
antibodies against RB51 antigens [73].
So far, there are no experiments that evaluated the
duration of immunity, but Olsen and Stoffregen [4] sug-
gest that a booster vaccination is required between 4
and 5 years of age to maintain high levels of protection
after RB51 calfhood vaccination. Also, RB51 revaccination
has been recommended six months and one year after calf-
hood vaccination in northern Mexico [74]. Nonetheless,
findings from blastogenic response of CD4+ and CD8+ T-
cells and the production of IFN-ɣ and IL-4 by the lympho-
cyte subsets six months after RB51 revaccination indicate
that there was no increase or improvement in the im-
munological response resulting from RB51-revaccination
of adult cattle [75]. Even though, RB51 revaccination may
still be considered as a tool for increasing herd immunity,
since not all animals are completely protected after pri-
mary immunization [50]. Furthermore, it has been demon-
strated that RB51 induces a strong Th1 cellular immune
response with production of IFN-γ and CD8+ specific cyto-
toxic cells, but not IL-4 after vaccination of mice [76].
5. 45/20 vaccine
This vaccine is prepared with heat-killed B. abortus bio-
var 1 strain 45/20 combined with oil adjuvant [77]. The
45/20 is a rough B. abortus, derived of smooth strain 45/
0 after 20 passages through guinea pigs [78]. This bac-
terin was used in some European Union countries for B.
abortus control replacing S19, in order to eliminate the
problems related to the induction of antibodies interfering
in the routine diagnosis of infection [5]. However, data of
experimental efficacy and immunologic response are
contradictory and mostly show the superiority of vaccin-
ation with S19 [79,80]. Furthermore, its use has some
drawbacks such as the use of oil adjuvant, needing of re-
peat vaccination and reversion to smooth strain when
used as a live vaccine [5,78]. Furthermore, some studies
have also indicated that 45/20 is not completely free of the
O-side chain [81], hence this vaccine can induce anti-
bodies detectable by routine serologic tests employed in
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ported protection, along with unpredictable serological ef-
fects and the occurrence of reactions at the site of vaccine
injection in some animals led to the interruption of the
use of 45/20 vaccine.
6. SR82 vaccine strain
The SR82 strain is a B. abortus biovar 6 live attenuated
vaccine used since 1974 by the former Union of Soviet
Socialist Republics (USSR) for bovine brucellosis control
[82]. This vaccine agglutinates in both rough and smooth
anti-sera, but does not induce positive response in brucel-
losis agglutination tests [82,83]. Moreover, SR82 induced
protection level similar to S19, after challenge with viru-
lent B. abortus, and it has been shown to be effective
under field conditions [82,83]. Currently the SR82 strain is
still massively used in the Russian Federation, Azerbaijan,
Tejikistan and other countries in the region [82].
7. Vaccination with recombinant genes, proteins,
vectors and B. abortus recombinant mutants
Classically and historically the vaccines used in the bo-
vine brucellosis control are live attenuated vaccines
produced from spontaneously attenuated or randomly
selected strains. Nonetheless, the numerous advances in
genomics, proteomics, recombinant DNA technology
and even in vaccinology, allowed the exploration of other
tools for the development of safer vaccines, without draw-
backs observed in classical vaccines. In this context, sev-
eral studies aimed to develop, test the efficacy or assess
the immulogical responses of the B. abortus genetically
engineered vaccines (recombinant genes, proteins, vectors
and modified B. abortus strains) have been performed es-
sentially in mice. However, with a few exceptions the ma-
jority of these recombinant vaccines, have not been tested
or did not protect cattle, their target species. Moreover, it
is important to take into account that recombinant vac-
cines, especially non-living ones, have limitations regard-
ing economic viability, need for multiple doses and the
need for combination of antigens.
7.1. DNA vaccines
DNA vaccines offer the possibility of inducing both cel-
lular and humoral responses, expression of antigens is
prolonged, they have better stability and do not require
refrigeration under storage. Therefore, several antigens
have been explored for their value as DNA vaccines against
B. abortus challenge, providing various levels of protection.
DNA vaccines encoding ribosomal L7/L12, lumazine syn-
thase (BLS), P39 (a putative periplasmic binding protein),
Omp16 (outer membrane protein) and BAB1_0278 genes
have demonstrated to confer protection against B. abortus
challenge in mice [22,23,27,42]. Moreover, Cu/Zn super-
oxide dismutase (Cu-Zn SOD) DNA vaccine induced aprotection level similar to the one induced by RB51 [25].
All these genes also proved capable of eliciting a desirable
cellular immune response in mice [22,23,32,33,42]. In
contrast, plasmid DNA carrying the BAB1_0263 and bacter-
ioferritin (BFR) genes did not induce significant level of pro-
tection against challenge with virulent B. abortus in mice.
Combined DNA vaccines have also demonstrated their
ability to protect better against challenge. DNA vaccines
of genes coding for an immundominant Brucella-antigen
(BCSP31) and promising Brucella-antigens (SOD and L7/
L12) provided significantly better protection than S19 in
mice [32]. This combined DNA vaccine also elicited sig-
nificantly higher cytotoxic response (granzyme B–produ-
cing CD8+ T cells) compared to S19-vaccinated mice [32].
Likewise, divalent fusion DNA vaccine encoding L7/L12
and Omp16 genes also proved to be effective and able to
elicit a strong T-cell proliferative response and induce a
large amount of IFN-γ producing T cells [27]. Addition-
ally, data showed that combination of these B. abortus
genes (BCSP31, SOD and L7/L12) withMycobacterium tu-
berculosis (Ag85B, MPT64, and MPT83) or Mycobacter-
ium bovis (Ag85B, MPT64, and MPT83) genes are very
promising for both agents [33,34]. DNA vaccine contain-
ing six genes encoding immunodominant antigens from
M. bovis and B. abortus induced protection comparable to
S19 and better than Bacillus Calmette-Guerin (BCG)
vaccine in cattle, suggesting that this is a highly promis-
ing vaccine for both diseases [34]. Combined DNA vac-
cine containing M. tuberculosis and B. abortus genes
with added IL-12 adjuvant system showed that besides the
high level of protection, IL-12 acts as an adjuvant to en-
hance protective immunity against M. tuberculosis and B.
abortus in challenge mice [33]. Conversely, results suggest
that a SOD DNA vaccine fused to IL-2 did not improve
protection efficacy [29].
However, despite some of B. abortus DNA vaccine
candidates have shown very promising results in mice,
the need of at least four booster vaccinations to be ef-
fective as well as the high cost for use in large animals,
make this type of vaccine impractical for cattle, the main
target of brucellosis vaccination. Moreover, excluding
mouse studies practically no DNA vaccine has been ex-
plored in natural hosts.
7.2. Subunit vaccines
Many of the same antigens tested as DNA vaccines have
also been evaluated as potential antigens for subunit
vaccines (L7/L12 ribosomal protein; P39; BLS; Omp16;
Cu/Zn SOD) [14,21,24,37,40]. The outer membrane
proteins (OMPs) of B. abortus, potential immunogenic
antigens, have been widely explored as subunit vaccines
[37,39,43,45]. Unlipidated recombinant Omp16 and
Omp19, and recombinant Omp25 liposome encapsu-
lated gave protection comparable to S19 in vaccinated
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unit vaccine increased resistance against challenge with
virulent B. abortus but at lower level than live attenu-
ated vaccines [43].
Similarly, flagellar proteins have been screened in search
for a subunit vaccine antigen candidate. Five flagellar genes,
although Brucella spp. are non-motile, (BAB1_0260 (FlgJ);
BAB2_0122 (FliN); BAB2_0150; BAB2_1086; BAB2_1093)
were evaluated for their ability to induce humoral and
cell-mediated responses and protect mice against B. abor-
tus challenge [84]. Of these, FlgJ and FliN were found to
be protective antigens that produced humoral and cell-
mediated responses in mice.
Moreover, recombinant proteins of other proven or
putative pathogenesis-associated genes such as L7/12,
BLS, rSurA and rDnaK induced different levels of protect-
ive immunity and cellular immune response in mice
against brucellosis [14,24,31]. Whereas, dihydrolipoamide
succinyltransferase (rE2o) and cysteine synthase A (rCysK)
provided partial protection against B. abortus challenge
and induced primarily Th2 type of immune response
[41,46]. Furthermore, CobB, AsnC and P39 elicit
protective immunity similarly to Cu/Zn SOD and S19,
which is marked by both humoral and cellular immune
responses [21,85]. Also, Cu/Zn SOD recombinant protein
(liposomes encapsulated) confers resistance in mice, further
increased upon co-immunization with recombinant IL-18
[40]. In contrast, BAB1_0560, BAB1_1108, BAB2_0059
(VirB10), BAB2_0191, BAB2_0423 (GntR) and BRF
protein vaccines did not induce protective immune
response [21,85].
The potential use of B. abortus subunit vaccines under
field conditions is very limited, although some encouraging
results showed. The requirement of multiple boosters, ad-
juvants and combination of several antigens makes it eco-
nomically unsuitable for cattle. Moreover, it is important to
consider that the response observed in mice may not re-
flect the protection achieved in natural hosts after vaccin-
ation. Furthermore, to generate a strong and protective
immune response that can mimic the natural infection
from a combination of few proteins of the pathogen is a
hard and complex challenge.
7.3. Vector vaccines
Alternatively, genes encoding immunodominant B. abor-
tus antigens can be introduced into attenuated viruses or
bacteria that serve as vector vaccines. B. abortus genes
have been successfully expressed in viruses (Semliki
Forest virus and Vaccinia virus) and bacteria (Escheri-
chia coli, Ochrobactrum anthropi, Lactococcus lactis,
Salmonella enterica subsp enterica serovar Typhimur-
ium and B. abortus) [16,20,26,28,35,38,44,86]. Escheri-
chia coli, O. anthropi (plus unmethylated CpG motifs)
and L. lactis expressing Cu/Zn SOD antigen ofB. abortus were able to elicit a Th1 immune response
and to protect mice following challenge with virulent
B. abortus [20,28,44,86]. Likewise, Semliki Forest virus-
based vector carrying RNA encoding Brucella translation
initiation factor 3 (IF3) showed a significant level of pro-
tection against a challenge with B. abortus 2308 in mice
[35]. L7/L12 protein carried by S. enterica serovar typhi-
murium but not by Vaccinia virus conferred protective ef-
ficacy and immunogenicity [26,38]. Also, vaccinia virus
carrying 18-kDa OMP of B. abortus were not able to pro-
tect mice against a challenge with the virulent strain B.
abortus 2308 [87].
The expression of B. abortus antigens on viral or bac-
terial vectors is a superior alternative to DNA and sub-
unit vaccines, as it closely mimics the natural infection,
allowing the modulation of the host immune response
and the multiplication of the initial number of antigen
copies within the host. However, despite not having some
of the inconveniences observed in non-living vaccines, as
multiple doses, need for adjuvant and high cost, other or-
ganisms expressing B. abortus proteins still need the per-
fect grouping of antigens, expressed in high amount to be
effective. The amount of foreign protein expressed by the
carrier organism needs to be able to promote a specific
protection. Moreover, the use of viral platform implies in
small chance that the vector DNA is integrated into the
genome of the host cell. In addition, although promising
most of these above vaccines have failed or have not been
tested in cattle, the target species, so no conclusion could
be drawn at this time.
7.4. B. abortus recombinant mutants
Another focus of research for new vaccines to protect
against B. abortus infection has been the construction of
RB51 recombinant mutants, which retain the rough
phenotype and attenuation but have improved characteris-
tics such as immunogenicity and protection against a chal-
lenge [17–19]. Hence, some studies have shown that the
complementation of RB51 with a functional wboA gene
(RB51WboA), which lead to the expression of O-side
chain in its cytoplasm, or the overexpression of Cu/Zn
SOD protein (RB51SOD) results in significant enhance-
ment of the vaccine efficacy against challenge with virulent
B. abortus in mice [17,18]. Furthermore, the combination
of these two genes in a single RB51 strain (RB51SOD/
wboA) also significantly increased the protective ability of
this RB51 recombinant vaccine in mice and did not alter
its desirable characteristics [19]. Nonetheless, this RB51-
recombinant strain was not as effective as the parental
RB51 strain in calfhood vaccination of bison after chal-
lenge with 2308 [36].
Besides RB51, B. abortus strain 2308 has also been
tested as recombinant mutant vaccine; the deletion of the
gene znuA, important protein for survival and normal
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capable of conferring protection similar to S19 or RB51
against challenge with parental 2308 in mice [30]. Experi-
ments in natural hosts, cattle, showed that the double gene
deletion (htrA cycL) PHE1 was attenuated in the bovine host
when compared to the virulent parental 2308 [88]. However,
due the absence of a standard challenge study using this po-
tential vaccine, the meaning of such data is unclear. Recom-
binant mutants based on deletion of ABC transporter
ATPase (BAB1_0542) or phosphoglycerate kinase (pgk) gene
of B. abortus 2308 also showed protection against challenge
with virulent strain in mice and the critical role of these
genes for full bacterial virulence [89,90]. In addition to the
virulence attenuation, it is desired that these B. abortus mu-
tants also show no interference with the diagnostics tests,
hence genes associated to the smooth phenotype have been
explored in the generation of deleted vaccines. Rough mu-
tant generated by wboA gene deletion of S19 protected mice
against challenge with 2308 and did not induce abortion in
pregnant sheep, showing promising results to be explored in
the future development of rough vaccines [91].
The improvement of the existing B. abortus vaccines
or the creation of new attenuated vaccines by deletion
or complementation of some genes seems to be the most
promising direction to find a safer and more efficient
substitute for the known B. abortus vaccines. Modified
live vaccines are highly effective in comparison to killed
vaccines. This is most likely due to strong and protective
cellular immune response induced by live vaccines [2,3].
The use of this platform avoids the main disadvantages
related to the non-living vaccines, as multiple delivery,
low immunogenicity, need for adjuvants and high cost.
Furthermore, B. abortus strains, even if genetically modi-
fied, can colonize, be immunogenic, and therefore per-
fectly simulate the natural infection. They are able to
multiply within animals for a short period expressing
in vivo protective antigens. The major advantage of this
approach over the use of vectors is that recombinant
mutants share most of proteins with B. abortus field
strains, whereas carrier organisms are able of expressing
only few Brucella antigens. However, a real concern on
B. abortus mutant strains is the presence of antibiotic
selection marker. The antibiotic marker is used in the
screening of transformed clones, but it is not desirable
in the final vaccine due to the potential of spreading
antibiotic resistance genes. Options, as an RB51 leucine
auxotroph, have been explored to avoid this issue [92].
Additionally, so far, there is no data available to exclude
the possibility that these live mutants will not have simi-
lar safety and diagnostic issues as live strains, especially
if made from smooth strains. Also, to move forwards in
the control of bovine brucellosis, these recombinant mu-
tants must be evaluated in cattle and other target animal
species. There is still a worldwide need for a vaccine thatis safe and highly efficacious in natural hosts, since the
transmission of disease occurs from cattle to people. The
results obtained in mice, although favorable for some vac-
cines, have to be interpreted according to their limitations,
as they cannot be directly extrapolated to cattle.
On another point of view about the usefulness of B.
abortus mutant as vaccines, S19 and RB51, the widely used
B. abortus vaccines, has been investigated as potential vec-
tors for heterologous protein expression, mainly using pro-
tective antigens important for other diseases of veterinary
interest [93–96]. In this context, multivalent recombinant
RB51 vaccines expressing Neospora caninum or M. bovis
proteins have been shown to induce antigen specific im-
mune response to heterologous antigens and, in the case of
N. caninum, was also achieved significant level of protec-
tion in mice [93,94]. Likewise, S19 carrying the genes en-
coding for the heterologous antigens of Babebia bovis or
M. bovis demonstrated successful specific cellular immune
response to recombinant proteins in mouse model [95,96].
These above bivalent live modified B. abortus candidate
vaccines need further evaluation as to their ability to in-
duce protective immune response as well lack of interfer-
ence in the diagnostic tests.
8. Other B. abortus potential vaccines
Besides B. abortus recombinants vaccines, also vaccines
based on outer membrane vesicles (OMVs) has been
exploited as an acellular alternative to live vaccines [97].
OMVs are bilayer membrane vesicles release by Gram-
negative and Gram-positive bacteria, which have been asso-
ciated to many processes such as release of virulent factors,
DNA transfer, regulation of host immune response and sur-
vival in the host cell [98]. B. abortus OMVs are mainly com-
posed for outer membrane proteins (Omps) and have been
associated with modulation of host immune response by in-
hibition of TNF-α and IL-8 response, inhibition of IFN-γ in-
duced expression of MHC class II molecules on human
monocytes and increase in expression of adhesion molecules
[97–99]. A Brucella melitensis vaccine based on OMVs has
been tested and showed promising results in BALB/c mice
[100]. Furthermore, it is already available a vaccine based
on OMVs, against meningococcus serogroup B (Neisseria
meningitides) in some countries as Cuba, Norway and
New Zealand [97]. Therefore, it is possible to speculate that
an OMV vaccine against B. abortus has a great potential to
be considered as part of the continuous efforts to reach safer
and more effective B. abortus vaccine. Nonetheless, due to
its high cost and laborious production, OMV is a more suit-
able approach for human vaccines, being impracticable for
cattle bearing in mind the technologies currently available.
9. Conclusions
Vaccination is a determinant strategy for brucellosis con-
trol and eradication programs, therefore it has been the
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some effective vaccines are available to control the dis-
ease in cattle. S19 and RB51 are the officially approved
B. abortus vaccine strains more widely and successfully
used to prevent bovine brucellosis worldwide. However,
due to some side effects shown by these current vac-
cines, plus the advances in recombinant DNA technol-
ogy and the lack of a vaccine for humans, there is an on
going extensive efforts focused on the development of
new and better vaccines. Engineered vaccines have the
potential to be the future of the bovine and human bru-
cellosis control, but many studies are still needed to de-
velop a better vaccine than the current vaccines in terms
of safety, efficacy and other desirable characteristics.
Moreover, it is important to consider that, mainly non-
living recombinant vaccines, also present important is-
sues, as the requirement of multiple boosters, adju-
vants, and optimal combination of antigens, besides
usually inducing poor cellular immune response. In
addition, although the excellent results observed for
some recombinant vaccines in mice, very few of these
candidate vaccines have been evaluated in cattle. The
recent studies indicate that the future of a new B. abor-
tus vaccine will be the construction of directed mu-
tants, which exclude the drawbacks and simultaneously
increase immunogenic characteristics presented by S19
and RB51. Furthermore, concerning the immune response
induced after S19 and RB51 vaccination in cattle, as well
as after RB51 revaccination, very little is understood.
Efforts to find out the principal characteristics of the im-
mune response triggered in cattle by the two most used
and successful B. abortus vaccine strains are essential to
try to establish an ideal vaccine. The definition of im-
mune markers correlated with protection, by mathemat-
ical modeling or evaluation of the immune response in
vaccine - challenge studies - would be very helpful in
the screening of B. abortus candidate vaccines.
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